Akebia Therapeutics, Inc. (AKBA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Akebia Therapeutics is a commercial-stage biopharmaceutical company focused on kidney disease. Its portfolio includes two FDA-approved products: Auryxia (ferric citrate), which lost exclusivity in March 2025 and faced generic competition from Teva in March 2026, and Vafseo (vadadustat), approved for anemia in dialysis-dependent CKD patients and launched in the U.S. in January 2025. The company also maintains a pipeline of mid-stage assets (praliciguat, ebribafusp) and early-stage candidates.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $49.1 million | $62.5 million | $102.7 million | $119.8 million |
| Product Revenue | $46.8 million | $60.5 million | $98.8 million | $116.3 million |
| Net Income (Loss) | $(8.9) million | $0.2 million | $(18.0) million | $6.4 million |
| Operating Loss | $(6.3) million | $14.1 million | $(11.0) million | $27.6 million |
| Cash & Equivalents | $155.5 million | $184.8 million | $155.5 million | $184.8 million |
| Total Debt (Current + Long-term) | $49.6 million | $48.3 million | $49.6 million | $48.3 million |
| Stockholders' Equity | $25.0 million | $32.6 million | $25.0 million | $32.6 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 21% year-over-year in Q2 2026. Product revenue dropped 23% primarily due to a significant decline in Auryxia sales following the March 2026 market entry of Teva's generic version. This was partially offset by a 60% increase in Vafseo revenue ($21.3M vs. $13.3M).
- Profitability Shift: The company reported a net loss of $8.9 million in Q2 2026, compared to a net income of $0.2 million in Q2 2025. Operating expenses increased 17% to $45.0 million, driven by a $1.9 million restructuring charge and higher R&D costs.
- Inventory Write-downs: Cost of goods sold increased due to inventory write-downs of $1.7 million in Q2 2026 (compared to immaterial amounts in Q2 2025) related to excess and obsolescence.
- Restructuring: In June 2026, the company implemented a commercial reorganization to improve efficiency, resulting in a headcount reduction of approximately 13% and a $1.9 million restructuring charge.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2026, the company held $155.5 million in cash. Management believes resources are sufficient to fund operations for at least 12 months, contingent on refinancing the senior secured term loan (BlackRock Credit Agreement) to defer principal payments due in January 2027.
- Vafseo Pricing Outlook: The company anticipates a significant decrease in Vafseo revenue in 2027 as the product transitions from the Transitional Drug Add-on Payment Adjustment (TDAPA) period to the post-TDAPA period. Pricing is expected to align with Erythropoiesis Stimulating Agents (ESAs), which are priced significantly lower than current Vafseo levels.
- Debt Obligations: The company has a $55.0 million senior secured term loan facility with BlackRock. Interest-only payments are required through December 31, 2026. The agreement includes covenants requiring either a minimum cash balance of $15.0 million or trailing twelve-month revenue of $150.0 million.
- Key Risks:
- Generic Competition: Continued erosion of Auryxia revenue due to generic entrants (Teva and authorized generic).
- Reimbursement: Uncertainty regarding post-TDAPA reimbursement rates for Vafseo starting in 2027.
- Supply Chain: Reliance on third-party manufacturers in China (WuXi STA) and Canada (Patheon), subject to geopolitical risks and potential trade tariffs.
- Capital Needs: Requirement for substantial additional financing to fund pipeline development and commercialization efforts.
Investor Verification Checklist
- Verify the status of the BlackRock term loan refinancing and the company's ability to meet the $150M trailing twelve-month revenue covenant or maintain the $15M cash minimum.
- Monitor Auryxia market share trends post-Teva generic launch to assess the rate of revenue erosion.
- Review Vafseo adoption rates among major dialysis organizations (DaVita, Fresenius, USRC) and the impact of the upcoming TDAPA expiration on pricing strategy.
- Assess the impact of U.S. trade tariffs and the BIOSECURE Act on the company's supply chain, specifically regarding WuXi AppTec (WuXi STA).
- Track progress of pipeline assets (ebribafusp, praliciguat) and associated milestone payment obligations.